Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12

Vaccine

Volumn 27, Issue 5, 2009, Pages 701-707

  Riezebos Brilman, Annelies ^a   Regts, Joke ^a   Chen, Margaret ^b,c   Wilschut, Jan ^a   Daemen, Toos ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Odontology ^*  (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

Alphavirus vector; CTL; HPV; Immunisation; Interleukin 12; Semliki Forest virus

Indexed keywords

INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS VECTOR; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL STRAIN BHK; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REGIMEN; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; TRANSGENIC MOUSE; TUMOR XENOGRAFT; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CRICETINAE; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; GENETIC VECTORS; HUMANS; IMMUNIZATION, SECONDARY; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS; PAPILLOMAVIRUS VACCINES; SEMLIKI FOREST VIRUS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 58149510113     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.032     Document Type: Article

References (46)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
2. Munger K., and Howley P.M. Human papillomavirus immortalization and transformation functions. Virus Res 89 2 (2002) 213-228
3. Eiben G.L., da Silva D.M., Fausch S.C., Le Poole I.C., Nishimura M.I., and Kast W.M. Cervical cancer vaccines: recent advances in HPV research. Viral Immunol 16 2 (2003) 111-121
4. Ferenczy A., Coutlee F., Franco E., and Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 169 5 (2003) 431-434
5. Frisch M., Biggar R.J., and Goedert J.J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 92 18 (2000) 1500-1510
6. Sillman F.H., Sentovich S., and Shaffer D. Ano-genital neoplasia in renal transplant patients. Ann Transpl 2 4 (1997) 59-66
7. Sun X.W., Kuhn L., Ellerbrock T.V., Chiasson M.A., Bush T.J., and Wright Jr. T.C. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337 19 (1997) 1343-1349
8. Frazer I.H. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4 1 (2004) 46-54
9. Riezebos-Brilman A., de Mare A., Bungener L., Huckriede A., Wilschut J., and Daemen T. Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol 35 3 (2006) 233-243
10. Daemen T., Regts J., Holtrop M., and Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther 9 2 (2002) 85-94
11. Daemen T., Riezebos-Brilman A., Bungener L., Regts J., Dontje B., and Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 21 11-12 (2003) 1082-1088
12. Daemen T., Riezebos-Brilman A., Regts J., Dontje B., van der Zee A., and Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 9 5 (2004) 733-742
13. Bungener L., de Mare A., Vries-Idema J., Sehr P., van der Zee A., Wilschut J., et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 11 6 (2006) 717-727
14. Riezebos-Brilman A., Regts J., Freyschmidt E.J., Dontje B., Wilschut J., and Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Ther 12 18 (2005) 1410-1414
15. Riezebos-Brilman A., Walczak M., Regts J., Rots M.G., Kamps G., Dontje B., et al. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer. Gene Ther 14 24 (2007) 1695-1704
16. Barnard P., Payne E., and McMillan N.A. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 277 2 (2000) 411-419
17. Evans E.M., Man S., Evans A.S., and Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57 14 (1997) 2943-2950
18. Ressing M.E., van Driel W.J., Celis E., Sette A., Brandt M.P., Hartman M., et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 56 3 (1996) 582-588
19. Youde S.J., Dunbar P.R., Evans E.M., Fiander A.N., Borysiewicz L.K., Cerundolo V., et al. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Cancer Res 60 2 (2000) 365-371
20. Steinman R.M., and Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 99 1 (2002) 351-358
21. Tindle R.W. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2 1 (2002) 59-65
22. Mazzolini G., Prieto J., and Melero I. Gene therapy of cancer with interleukin-12. Curr Pharm Des 9 24 (2003) 1981-1991
23. Hsieh C.S., Macatonia S.E., Tripp C.S., Wolf S.F., O'Garra A., and Murphy K.M. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260 5107 (1993) 547-549
24. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177 4 (1993) 1199-1204
25. Tsung K., Meko J.B., Peplinski G.R., Tsung Y.L., and Norton J.A. IL-12 induces T helper 1-directed antitumor response. J Immunol 158 7 (1997) 3359-3365
26. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249
27. Lin K.Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56 1 (1996) 21-26
28. Auewarakul P., Gissmann L., and Cid-Arregui A. Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors. Mol Cell Biol 14 12 (1994) 8250-8258
29. Colmenero P., Chen M., Castanos-Velez E., Liljestrom P., and Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 98 4 (2002) 554-560
30. Gazzinelli R.T., Wysocka M., Hayashi S., Denkers E.Y., Hieny S., Caspar P., et al. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 153 6 (1994) 2533-2543
31. Gherardi M.M., Ramirez J.C., Rodriguez D., Rodriguez J.R., Sano G., Zavala F., et al. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner. J Immunol 162 11 (1999) 6724-6733
32. Grohmann U., Bianchi R., Ayroldi E., Belladonna M.L., Surace D., Fioretti M.C., et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol 158 8 (1997) 3593-3602
33. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., and Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 165 10 (2000) 5713-5719
34. Curtsinger J.M., Schmidt C.S., Mondino A., Lins D.C., Kedl R.M., Jenkins M.K., et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol 162 6 (1999) 3256-3262
35. Schmidt C.S., and Mescher M.F. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo. J Immunol 163 5 (1999) 2561-2567
36. Asselin-Paturel C., Lassau N., Guinebretiere J.M., Zhang J., Gay F., Bex F., et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther 6 4 (1999) 606-615
37. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., and Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87 8 (1995) 581-586
38. Yao L., Pike S.E., Setsuda J., Parekh J., Gupta G., Raffeld M., et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96 5 (2000) 1900-1905
39. Chikkanna-Gowda C.P., Sheahan B.J., Fleeton M.N., and Atkins G.J. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12 16 (2005) 1253-1263
40. Rodriguez-Madoz J.R., Prieto J., and Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 12 1 (2005) 153-163
41. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., and Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol Immunother 52 3 (2003) 133-144
42. Mortarini R., Borri A., Tragni G., Bersani I., Vegetti C., Bajetta E., et al. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12. Cancer Res 60 13 (2000) 3559-3568
43. Gherardi M.M., Ramirez J.C., and Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74 14 (2000) 6278-6286
44. Jin H.S., Park E.K., Lee J.M., NamKoong S.E., Kim D.G., Lee Y.J., et al. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor. Gynecol Oncol 97 2 (2005) 559-567
45. Bermudez-Humaran L.G., Cortes-Perez N.G., Lefevre F., Guimaraes V., Rabot S., Alcocer-Gonzalez J.M., et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 175 11 (2005) 7297-7302
46. Seaman M.S., Peyerl F.W., Jackson S.S., Lifton M.A., Gorgone D.A., Schmitz J.E., et al. Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J Virol 78 1 (2004) 206-215